Every individual reacts differently to drugs and to understand this modulation we need to accurately assess an individual’s underlying genetic variation while prioritizing mutations that affect the phenotype. My project will develop and deploy an approach called "Variant Technology" or "V-Tech" to build a comprehensive map of all clinically actionable human variants in crucial drug targets. V-Tech will work by screening genetically engineered humanized yeast cells in a parallel functional assay that quantifies drug resistance and sensitivity. Currently, there is little information about factors influencing drug effectiveness. V-Tech can bridge this gap by quantitating all possible variants by drug response.